Literature DB >> 7333448

A study on the relationship between the prognosis of chronic active hepatitis and the HBV associated antigen/antibody systems.

Y Kosaka, Y Tameda, Y Okuda, K Takase, H Sawa, H Takezawa.   

Abstract

The relationship between the prognosis of the disease based on liver histology and HB virus (HBV) associated antigen/antibody systems was investigated in twenty seven patients with chronic active hepatitis (CAH). These patients were followed up over extended periods with mean duration of 44.3 months. On initial liver biopsy five of twelve patients with CAH with spotty or focal necrosis were HBs antigen (HBsAg) positive, as were also five of six patients with sublobular necrosis and six of nine patients with lobular disorganization. Most of the HBsAg negative patients were anti-HBs or anti-HBc positive: HBV associated antigen or antibody was completely undetectable in only three of the twenty seven patients. There was no difference in the frequency of progression to liver cirrhosis (LC) between the sixteen HBsAg positive and the eleven HBsAg negative patients with CAH. On the other hand, progression to LC occurred in only one of seven HBe antigen (HBeAg) negative patients, compared to four of nine HBeAg positive patients, who were HbsAg positive. There were four patients who were HBeAg positive initially but then became HBeAg negative in the course of observation. LC developed in two of these four patients. These results suggest that in HBsAg positive patients with CAH the presence or absence of HBeAg and the variation in its level can provide useful indicators of the prognosis of the disease.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7333448     DOI: 10.1007/bf02813794

Source DB:  PubMed          Journal:  Gastroenterol Jpn        ISSN: 0435-1339


  23 in total

1.  Hepatits A virus infection in fulminant hepatitis and chronic active hepatitis.

Authors:  J Rakela; A G Redeker; V M Edwards; R Decker; L R Overby; J W Mosley
Journal:  Gastroenterology       Date:  1978-05       Impact factor: 22.682

2.  New specificities in Australia antigen positive sera distinct from the Le Bouvier determinants.

Authors:  L O Magnius; J A Espmark
Journal:  J Immunol       Date:  1972-11       Impact factor: 5.422

3.  [Prognostic evaluation of chronic hepatitis with particular reference to the findings of repeated liver biopsy (author's transl)].

Authors:  Y Kosaka; Y Tameda; A Nishimura; K Takase; M Fujimoto; T Murayama; T Ito; S Tagawa; S Akeda; S Nakagiri; I Kondo; E Tsujita; Y Okuda; M Hagiwara; H Matsumoto; S Kakiuchi; M Kobayashi; M Hashizume
Journal:  Nihon Shokakibyo Gakkai Zasshi       Date:  1981-03

4.  Therapeutic evaluation of chronic aggressive nepatitis and its relation to the Australian antigen.

Authors:  A D Jorge; D Sanchez
Journal:  Acta Hepatogastroenterol (Stuttg)       Date:  1978-06

5.  Clinical significance of e-antigen/anti-e, with special reference to HBc-antigen in the liver.

Authors:  S Furuta; K Kiyosawa; A Nagata; Y Koike; T Sahara; K Furukawa; Y Iijima; S Yamamura; H Komatsu; K Kawahara; M Miura; Y Gibo; K Sodeyama; M Oda; F Tsuda; Y Akahane; M Mayumi
Journal:  Gastroenterol Jpn       Date:  1977

6.  Severe chronic active liver disease. Prognostic significance of initial morphologic patterns.

Authors:  S W Schalm; M G Korman; W H Summerskill; A J Czaja; A H Baggenstoss
Journal:  Am J Dig Dis       Date:  1977-11

7.  e System and intrahepatocelullar HBcAG and HBsAG in HBsAG positive patients with liver diseases and healthy carriers.

Authors:  G Hess; J O Nielsen; W Arnold; K H Büschenfelde
Journal:  Scand J Gastroenterol       Date:  1977       Impact factor: 2.423

8.  e Antigen-antibody system as indicator of liver damage in patients with hepatitis-B antigen.

Authors:  N El Sheikh; I L Woolf; R M Galbraith; A L Eddleston; I W Dymock; R Williams
Journal:  Br Med J       Date:  1975-11-01

9.  Transmission of non-A, non-B hepatitis.

Authors:  J H Hoofnagle; R J Gerety; E Tabor; S M Feinstone; L F Barker; R H Purcell
Journal:  Ann Intern Med       Date:  1977-07       Impact factor: 25.391

10.  Treatment of chronic active hepatitis with either prednisolone or corticotrophin: a controlled trial.

Authors:  G Giusti; F Piccinino; G Ruggiero; B Galanti; P E Lucchelli; G Manzillo; E Sagnelli; R Utili
Journal:  Acta Hepatogastroenterol (Stuttg)       Date:  1977-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.